BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 54,892 Shares

August 13, 2026 by InsiderTrades.com

Key Points

CEO John Oyler sold 54,892 shares of BeOne Medicines at an average price of $358.15, generating approximately $19.66 million and reducing his direct ownership by 18.57% to 240,743 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
Oyler has made several additional sales recently, including roughly $86.5 million of stock across August 10–12, which may concern investors but is less indicative of a new negative outlook because of the preset trading plan.
BeOne’s latest quarterly results exceeded expectations, with $2.05 in EPS versus the $1.40 consensus and revenue of $1.71 billion. Analysts remain broadly positive, giving the stock an average “Buy” rating and a $402.14 price target compared with its $359.05 opening price.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 54,892 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the sale, the chief executive officer directly owned 240,743 shares of the company's stock, valued at $86,222,105.45. This represents a 18.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

4 Stocks With Huge Cash Holdings at Silicon Valley Bank

John Oyler also recently made the following trade(s):

On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The shares were sold at an average price of $361.90, for a total transaction of $25,661,243.30.
On Monday, August 10th, John Oyler sold 115,011 shares of BeOne Medicines stock. The stock was sold at an average price of $357.87, for a total transaction of $41,158,986.57.
On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total transaction of $15,086,671.00.
On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total transaction of $19,503,984.99.
On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total transaction of $14,767,062.00.
On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15.
On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.

BeOne Medicines Stock Performance

ONC stock opened at $359.05 on Thursday. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The company has a market cap of $39.39 billion, a P/E ratio of 63.21 and a beta of 0.49. The business's fifty day moving average is $301.40 and its 200-day moving average is $309.13.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to analysts' expectations of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post 7.3 EPS for the current year.

Institutional Trading of BeOne Medicines

A number of large investors have recently bought and sold shares of the business. EFG International AG acquired a new stake in BeOne Medicines during the 4th quarter worth approximately $25,000. Leonteq Securities AG acquired a new position in shares of BeOne Medicines in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. acquired a new position in shares of BeOne Medicines in the second quarter valued at approximately $35,000. CWM LLC increased its position in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines during the fourth quarter worth $61,000. 48.55% of the stock is owned by institutional investors.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

Positive Sentiment: BeOne Medicines and Revolution Medicines announced a partnership covering the clinical development and regional commercialization of oncology therapies. The agreement could expand BeOne’s cancer-treatment portfolio and future commercial opportunities. BeOne and Revolution Medicines partner for oncology therapies
Positive Sentiment: Revolution Medicines shares rose after the market evaluated the BeOne-funded Phase 3 RAS(ON) collaboration, suggesting investors view the partnership as strategically meaningful for advancing targeted oncology treatments. The indirect benefit to ONC is tied to potential pipeline growth and future commercialization. Revolution Medicines rises after BeOne-funded Phase 3 RAS(ON) deal
Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The data does not indicate meaningful short-selling pressure, although the reported figures appear unusual and may have limited informational value.
Negative Sentiment: CEO John Oyler sold 240,810 BeOne Medicines shares across transactions dated August 10–12 for approximately $86.5 million in total. The sales reduced his direct ownership substantially, which can weigh on investor sentiment; however, all three transactions were executed under a pre-arranged Rule 10b5-1 trading plan, reducing the signal that the sales reflect a new negative view of the company. SEC insider transaction filing

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ONC. Guggenheim upped their price target on BeOne Medicines from $420.00 to $430.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Nomura upgraded shares of BeOne Medicines to a "strong-buy" rating in a report on Monday, July 27th. Morgan Stanley restated an "overweight" rating on shares of BeOne Medicines in a report on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BeOne Medicines in a research note on Friday, July 17th. Finally, TD Cowen increased their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BeOne Medicines currently has an average rating of "Buy" and an average target price of $402.14.

Read Our Latest Analysis on BeOne Medicines

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.